American medical technology giant Becton Dickinson and Co. (BD) has announced that Chris DelOrefice, Executive Vice President and Chief Financial Officer, will depart the company on December 5, 2025, to pursue a new professional opportunity.

Vitor Roque, currently Senior Vice President of Finance, Business Units and Corporate Financial Planning and Analysis, has been appointed interim CFO while BD undertakes a search for a permanent successor. Roque will assume the role following DelOrefice’s departure and will collaborate closely with him and the company’s leadership team to ensure a smooth transition.

"Chris has been an important part of our executive leadership team over the past four years as we delivered on our BD 2025 strategy and transformed our portfolio to lead in the evolving healthcare landscape," said Tom Polen, chairman, CEO and president of BD.

"As we transition, Vitor brings extensive knowledge of the company, having served in a broad range of finance leadership roles over his two decades at BD across our regions, business units and segments while also supporting key acquisitions. His strong finance and leadership capabilities position him well to serve as interim CFO as we continue to deliver on our strategic goals,” Polen added.

Alongside the transition announcement, BD also released unaudited preliminary results for the fourth quarter and full year fiscal 2025 ended September 30.

The company reported preliminary fourth-quarter unaudited revenue of approximately USD 5.9 billion, representing an estimated increase of approximately 8.3 percent on a reported basis, 7.0 percent on a currency-neutral basis and 3.9 percent on an organic basis.   

For the full fiscal year, BD achieved revenue of approximately USD 21.8 billion, an increase of around 8.2 percent on a reported basis, 7.7 percent on an adjusted currency-neutral basis and 2.9 percent on an organic basis.   

"While we continue to navigate a dynamic macro environment that had a greater than anticipated impact this quarter in areas we have been closely monitoring, specifically Pharmaceutical Systems vaccines and Biosciences academic and government research, we delivered strong growth across multiple areas including the BD Interventional segment, Advanced Patient Monitoring and Medication Delivery Solutions,” Polen noted.

“Looking ahead, we continue to execute on our strategy and are taking further action to unlock value, including investments in areas of opportunity to drive growth and continued margin momentum. I look forward to sharing more on our New BD strategy and expectations for fiscal 2026 on our upcoming earnings call,” he concluded.